menu
    • menu

    Find Regorafenib manufacturers, exporters & distributors on PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    18

    API Suppliers

    API Suppliers

    5

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    3

    EU WC

    EU WC

    3

    KDMF

    KDMF

    5

    NDC API

    NDC API

    0

    VMF

    NDC API

    14

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 0

    MARKET PLACE

    6

    API

    4

    FDF

    10INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    12

    FDF Dossiers

    FDF Dossiers

    2

    FDA Orange Book

    FDA (Orange Book)

    5

    Europe

    Europe

    1

    Canada

    Canada

    0

    Australia

    Australia

    1

    South Africa

    South Africa

    3

    Listed Dossiers

    Listed Dossiers

    6DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    6

    Others

    PATENTS & EXCLUSIVITIES

    4

    US Patents

    1

    US Exclusivities

    7

    Health Canada Patents

    DIGITAL CONTENT

    3

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    61

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    118,540,814

    Annual Reports

    4,058

    Finished Drug Prices

    Listed Dossiers

    104 RELATED EXCIPIENT COMPANIES

    178EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 755037-03-7, Bay 73-4506, Stivarga, 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-n-methylpicolinamide, Regorafenibum, Regorafenib (bay 73-4506)
    Molecular Formula
    C21H15ClF4N4O3
    Molecular Weight
    482.8  g/mol
    InChI Key
    FNHKPVJBJVTLMP-UHFFFAOYSA-N
    FDA UNII
    24T2A1DOYB
    Regorafenib
    Regorafenib is the anhydrous form of regorafenib, an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling.
    Regorafenib is a Kinase Inhibitor. The mechanism of action of regorafenib is as a Protein Kinase Inhibitor, and Cytochrome P450 2C9 Inhibitor.
    1 2D Structure

    Regorafenib

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide
    2.1.2 InChI
    InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)
    2.1.3 InChI Key
    FNHKPVJBJVTLMP-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F
    2.2 Other Identifiers
    2.2.1 UNII
    24T2A1DOYB
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-n-methylpyridine-2-carboxamide

    2. Bay 73-4506

    3. Bay-73-4506

    4. Bay73-4506

    5. Stivarga

    2.3.2 Depositor-Supplied Synonyms

    1. 755037-03-7

    2. Bay 73-4506

    3. Stivarga

    4. 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-n-methylpicolinamide

    5. Regorafenibum

    6. Regorafenib (bay 73-4506)

    7. Bay73-4506

    8. Bay-73-4506

    9. 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide

    10. Regorafenib-13c-d3

    11. 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-n-methylpyridine-2-carboxamide

    12. 24t2a1doyb

    13. Chembl1946170

    14. Chebi:68647

    15. Bay-734506

    16. Stivarga (tn)

    17. 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-n-methylpyridine-2-carboxamide

    18. Regorafenib [inn]

    19. Regorafenib [usan:inn]

    20. Unii-24t2a1doyb

    21. Fluoro-sorafenib

    22. 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl}amino)-3-fluorophenoxy)-n-methylpyridine-2-carboxamide

    23. Regorafenib [mi]

    24. Regorafenib (usan/inn)

    25. Regorafenib [vandf]

    26. Regorafenib Anhydrous

    27. Regorafenib [who-dd]

    28. Mls006010303

    29. Regorafenib Crystalline Form I

    30. Schembl432230

    31. Regorafenib,bay 73-4506

    32. Gtpl5891

    33. Dtxsid60226441

    34. Ex-a058

    35. Regorafenib - Bay 73-4506

    36. Bcpp000352

    37. Hms3654k16

    38. Hms3672e15

    39. Bcp02105

    40. Bkd17855

    41. Zinc6745272

    42. Bdbm50363397

    43. Mfcd16038047

    44. Nsc763932

    45. Nsc800865

    46. S1178

    47. Akos015951107

    48. Am81251

    49. Bay 734506

    50. Bcp9000384

    51. Ccg-269571

    52. Cs-0170

    53. Db08896

    54. Nsc-763932

    55. Nsc-800865

    56. Sb16819

    57. Ncgc00263138-01

    58. Ncgc00263138-13

    59. Ncgc00263138-19

    60. 2-pyridinecarboxamide,4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-n-methyl-

    61. 835621-08-4

    62. Ac-25075

    63. Ac-31116

    64. As-16304

    65. Hy-10331

    66. Smr004701370

    67. Ft-0674338

    68. R0142

    69. Sw218097-2

    70. Cas:835621-07-3;regorafenib Hydrochloride

    71. Regorafenib (bay73-4506,fluoro-sorafenib)

    72. A25020

    73. D10138

    74. Ab01565826_02

    75. Sr-01000941571

    76. Q3891664

    77. Sr-01000941571-1

    78. Brd-k16730910-001-02-4

    79. 2-pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-n-methyl-

    80. 4-[4-({[4-chloro-3-(trifluoromethy)phenyl]carbamoyl}amino)-3-fluorophenoxy]-1-methylpyridine-2-carboxamide

    81. 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic Acid Methylamide

    82. Regorafenib;1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(2-fluoro-4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea

    2.4 Create Date
    2006-10-26
    3 Chemical and Physical Properties
    Molecular Weight 482.8 g/mol
    Molecular Formula C21H15ClF4N4O3
    XLogP34.2
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count8
    Rotatable Bond Count5
    Exact Mass482.0768807 g/mol
    Monoisotopic Mass482.0768807 g/mol
    Topological Polar Surface Area92.4 Ų
    Heavy Atom Count33
    Formal Charge0
    Complexity686
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 2  
    Drug NameStivarga
    PubMed HealthRegorafenib (By mouth)
    Drug ClassesAntineoplastic Agent
    Drug LabelStivarga (regorafenib) has the chemical name 4-[4-({[4-chloro-3-(trifluoromethyl) phenyl] carbamoyl} amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate. Regorafenib has the following structural formula:Regorafenib is a monohydrate and...
    Active IngredientRegorafenib
    Dosage FormTablet
    Routeoral; Oral
    Strength40mg
    Market StatusPrescription
    CompanyBayer Healthcare Pharms; Bayer Hlthcare

    2 of 2  
    Drug NameStivarga
    PubMed HealthRegorafenib (By mouth)
    Drug ClassesAntineoplastic Agent
    Drug LabelStivarga (regorafenib) has the chemical name 4-[4-({[4-chloro-3-(trifluoromethyl) phenyl] carbamoyl} amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate. Regorafenib has the following structural formula:Regorafenib is a monohydrate and...
    Active IngredientRegorafenib
    Dosage FormTablet
    Routeoral; Oral
    Strength40mg
    Market StatusPrescription
    CompanyBayer Healthcare Pharms; Bayer Hlthcare

    4.2 Drug Indication

    Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumour (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. Regorafenib is also indicated for the treatment of patients with hepatocellular carcinoma (HCC) previously treated with sorafenib.

    FDA Label

    Stivarga is indicated as monotherapy for the treatment of adult patients with:

    - metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies - these include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy;

    - unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib;

    - hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

    5 Pharmacology and Biochemistry
    5.1 FDA Pharmacological Classification
    5.1.1 Active Moiety
    REGORAFENIB
    5.1.2 FDA UNII
    24T2A1DOYB
    5.1.3 Pharmacological Classes
    Kinase Inhibitor [EPC]; Protein Kinase Inhibitors [MoA]; Cytochrome P450 2C9 Inhibitors [MoA]
    5.2 ATC Code

    L01EX05

    L01XE21

    S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355

    L - Antineoplastic and immunomodulating agents

    L01 - Antineoplastic agents

    L01E - Protein kinase inhibitors

    L01EX - Other protein kinase inhibitors

    L01EX05 - Regorafenib

    5.3 Absorption, Distribution and Excretion

    Absorption

    Cmax = 2.5 g/mL; Tmax = 4 hours; AUC = 70.4 g*h/mL; Cmax, steady-state = 3.9 g/mL; AUC, steady-state = 58.3 g*h/mL; The mean relative bioavailability of tablets compared to an oral solution is 69% to 83%.

    Route of Elimination

    Approximately 71% of a radiolabeled dose was excreted in feces (47% as parent compound, 24% as metabolites) and 19% of the dose was excreted in urine (17% as glucuronides) within 12 days after administration of a radiolabeled oral solution at a dose of 120 mg.

    Volume of Distribution

    Regorafenib undergoes enterohepatic circulation with multiple plasma concentration peaks observed across the 24-hour dosing interval.

    5.4 Metabolism/Metabolites

    Regorafenib is metabolized by CYP3A4 and UGT1A9. The main circulating metabolites of regorafenib measured at steady-state in human plasma are M-2 (N-oxide) and M-5 (N-oxide and N-desmethyl), both of them having similar in vitro pharmacological activity and steady-state concentrations as regorafenib. M-2 and M-5 are highly protein bound (99.8% and 99.95%, respectively). Regorafenib is an inhibitor of P-glycoprotein, while its active metabolites M-2 (N-oxide) and M-5 (N-oxide and N-desmethyl) are substrates of P-glycoprotein.

    5.5 Biological Half-Life

    Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);

    5.6 Mechanism of Action

    Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment. In in vitro biochemical or cellular assays, regorafenib or its major human active metabolites M-2 and M-5 inhibited the activity of RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAFV600E , SAPK2, PTK5, and Abl at concentrations of regorafenib that have been achieved clinically. In in vivo models, regorafenib demonstrated anti-angiogenic activity in a rat tumor model, and inhibition of tumor growth as well as anti-metastatic activity in several mouse xenograft models including some for human colorectal carcinoma.

    API SUPPLIERS

    read-more
    read-more

    01

    Faran Shimi Pharmaceutical

    Iran

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothFaran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.

    Contact Supplier Contact Supplier
    Flag Iran
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Faran Shimi Pharmaceutical

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Jinan Tantu Chemicals

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI China
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothJinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Jinan Tantu Chemicals

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    MSN Laboratories

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Antibody Engineering
    Not Confirmed
    arrow

    MSN Laboratories

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Antibody Engineering
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2016-01-21

    Pay. Date : 2015-11-06

    DMF Number : 29870

    Submission : 2015-11-03

    Status : Active

    Type : II

     CEP/COS JDMF EU-WCarrow-down
    ✖

    Date of Issue : 2022-09-02

    Valid Till : 2025-05-05

    Written Confirmation Number : WC-0349

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 54893-0033

    Start Marketing Date : 2015-02-17

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

     KDMF arrow-down
    ✖

    Registrant Name : Aging Life Science Co., Ltd.

    Registration Date : 2022-03-14

    Registration Number : 434-45-ND

    Manufacturer Name : MSN Laboratories Private Limited

    Manufacturer Address : (Unit-ll) Sy. No. 50, 53, 53/A, 54 & 54/A, Kardanur (Village), Patancheru (Mandal), Sangareddy District, Telangana, 502 300, India.

     VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    MSN Laboratories

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Antibody Engineering
    Not Confirmed
    arrow

    MSN Laboratories

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Antibody Engineering
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 36838

    Submission : 2022-03-30

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 54893-0033

    Start Marketing Date : 2015-02-17

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

     KDMF arrow-down
    ✖

    Registrant Name : Aging Life Science Co., Ltd.

    Registration Date : 2022-03-14

    Registration Number : 434-45-ND

    Manufacturer Name : MSN Laboratories Private Limited

    Manufacturer Address : (Unit-ll) Sy. No. 50, 53, 53/A, 54 & 54/A, Kardanur (Village), Patancheru (Mandal), Sangareddy District, Telangana, 502 300, India.

     VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Zhejiang Huayi Pharmaceutical Co.,...

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Antibody Engineering
    Not Confirmed
    arrow

    Zhejiang Huayi Pharmaceutical Co.,...

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Antibody Engineering
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 39898

    Submission : 2024-04-27

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Hetero Drugs

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Antibody Engineering
    Not Confirmed
    arrow

    Hetero Drugs

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Antibody Engineering
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2016-07-06

    Pay. Date : 2016-05-02

    DMF Number : 30490

    Submission : 2016-05-13

    Status : Active

    Type : II

     CEP/COS JDMF EU-WCarrow-down
    ✖

    Date of Issue : 2022-09-16

    Valid Till : 2025-08-08

    Written Confirmation Number : WC-0041

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 68554-0092

    Start Marketing Date : 2012-09-27

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

     KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Chongqing Carelife Pharmaceutical

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Antibody Engineering
    Not Confirmed
    arrow

    Chongqing Carelife Pharmaceutical

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Antibody Engineering
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2023-08-14

    Pay. Date : 2023-05-08

    DMF Number : 38197

    Submission : 2023-04-26

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Shouyuan Chemical

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Antibody Engineering
    Not Confirmed
    arrow

    09

    Shouyuan Chemical

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Antibody Engineering
    Not Confirmed
    arrow

    10

    Teva Pharmaceutical Industries

    Israel

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Antibody Engineering
    Not Confirmed
    arrow

    Teva Pharmaceutical Industries

    Israel

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Antibody Engineering
    Not Confirmed
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    USDMF

    read-more
    read-more

    01

    Medlab Asia & Asia Health
    Not Confirmed

    01

    Chongqing Carelife Pharmaceutical Co...

    China
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    GDUFA

    DMF Review : Complete

    Rev. Date : 2023-08-14

    Pay. Date : 2023-05-08

    DMF Number : 38197

    Submission : 2023-04-26

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Hetero Labs Ltd

    India

    USDMF

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    02

    Hetero Labs Ltd

    India
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    GDUFA

    DMF Review : Complete

    Rev. Date : 2016-07-06

    Pay. Date : 2016-05-02

    DMF Number : 30490

    Submission : 2016-05-13

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Medlab Asia & Asia Health
    Not Confirmed

    03

    Msn Laboratories Private Ltd

    India
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    GDUFA

    DMF Review : Complete

    Rev. Date : 2016-01-21

    Pay. Date : 2015-11-06

    DMF Number : 29870

    Submission : 2015-11-03

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Medlab Asia & Asia Health
    Not Confirmed

    04

    Msn Laboratories Private Ltd

    India
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 36838

    Submission : 2022-03-30

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Medlab Asia & Asia Health
    Not Confirmed

    05

    Zhejiang Huayi Pharmaceutical Co Ltd

    China
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 39898

    Submission : 2024-04-27

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial

    Details:

    PRO-140 (leronlimab) a monoclonal antibody works by blocking the activity of the CCR5 receptor, being developed in combination with Regorafenib for MSS mCRC.


    Lead Product(s): Leronlimab,Regorafenib

    Therapeutic Area: Oncology Brand Name: PRO-140

    Study Phase: Phase IIProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 04, 2024

    blank

    01

    CytoDyn

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    CytoDyn

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Leronlimab,Regorafenib

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial

    Details : PRO-140 (leronlimab) a monoclonal antibody works by blocking the activity of the CCR5 receptor, being developed in combination with Regorafenib for MSS mCRC.

    Brand Name : PRO-140

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    November 04, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RRx-001 + Irinotecan Significantly Improved Progression Free Survival (PFS) Versus Regorafenib in the Randomized Phase 2 ROCKET Trial in Advanced Colore...

    Details:

    RRx-001 is a highly selective NLRP3 inhibitor with vascular normalization and tumor associated macrophage polarization properties that resensitizes tumors to previously administered therapies.


    Lead Product(s): RRx-001,Regorafenib,Bevacizumab

    Therapeutic Area: Oncology Brand Name: RRx-001

    Study Phase: Phase IIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 14, 2022

    blank

    02

    EpicentRx

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    EpicentRx

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : RRx-001,Regorafenib,Bevacizumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    RRx-001 + Irinotecan Significantly Improved Progression Free Survival (PFS) Versus Regorafenib in ...

    Details : RRx-001 is a highly selective NLRP3 inhibitor with vascular normalization and tumor associated macrophage polarization properties that resensitizes tumors to previously administered therapies.

    Brand Name : RRx-001

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    December 14, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Global Coalition for Adaptive Research Announces That Regorafenib Has Completed Follow-up in the GBM AGILE Trial for Patients With Glioblastoma

    Details:

    Regorafenib (stivarga) is an oral multikinase inhibitor that potently blocks multiple protein kinases, including kinases involved in oncogenesis, tumor angiogenesis, and tumor immunity.


    Lead Product(s): Regorafenib

    Therapeutic Area: Oncology Brand Name: Stivarga

    Study Phase: Phase II/ Phase IIIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 21, 2022

    blank

    03

    Global Coalition for Adaptive Research

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Global Coalition for Adaptive Research

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Regorafenib

    Therapeutic Area : Oncology

    Highest Development Status : Phase II/ Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Global Coalition for Adaptive Research Announces That Regorafenib Has Completed Follow-up in the G...

    Details : Regorafenib (stivarga) is an oral multikinase inhibitor that potently blocks multiple protein kinases, including kinases involved in oncogenesis, tumor angiogenesis, and tumor immunity.

    Brand Name : Stivarga

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    September 21, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Bayer Demonstrates Commitment to Advancing Oncology by Showcasing New Data From Innovative Science at ESMO Congress 2022

    Details:

    stivarga (regorafenib) is an oral multikinase inhibitor that potently blocks multiple protein kinases, including kinases involved in oncogenesis, tumor angiogenesis, and tumor immunity.


    Lead Product(s): Regorafenib,Nivolumab

    Therapeutic Area: Oncology Brand Name: Stivarga

    Study Phase: Phase IIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 30, 2022

    blank

    04

    Bayer AG

    Germany
    arrow
    Antibody Engineering
    Not Confirmed

    Bayer AG

    Germany
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Regorafenib,Nivolumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Bayer Demonstrates Commitment to Advancing Oncology by Showcasing New Data From Innovative Science...

    Details : stivarga (regorafenib) is an oral multikinase inhibitor that potently blocks multiple protein kinases, including kinases involved in oncogenesis, tumor angiogenesis, and tumor immunity.

    Brand Name : Stivarga

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    August 30, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Bayer to Showcase New Data from Evolving Oncology Portfolio

    Details:

    Presentations will highlight differentiated therapies from Bayer that improve patient outcomes, as well as explore efficacy and safety of treatments in different tumor types and in combination with immunotherapies.


    Lead Product(s): Regorafenib

    Therapeutic Area: Oncology Brand Name: Stivarga

    Study Phase: Phase IIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 08, 2020

    blank

    05

    Bayer AG

    Germany
    arrow
    Antibody Engineering
    Not Confirmed

    Bayer AG

    Germany
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Regorafenib

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Bayer to Showcase New Data from Evolving Oncology Portfolio

    Details : Presentations will highlight differentiated therapies from Bayer that improve patient outcomes, as well as explore efficacy and safety of treatments in different tumor types and in combination with immunotherapies.

    Brand Name : Stivarga

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    September 08, 2020

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib

    Details:

    This is the first global study carried out as a collaboration between CStone and Bayer assessing the safety, tolerability, pharmacokinetics, and antitumor activity of the CS1001 plus regorafenib combination in cancer.


    Lead Product(s): Sugemalimab,Regorafenib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase I/ Phase IIProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 24, 2020

    blank

    06

    CStone Pharmaceuticals

    China
    arrow
    Antibody Engineering
    Not Confirmed

    CStone Pharmaceuticals

    China
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Sugemalimab,Regorafenib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination...

    Details : This is the first global study carried out as a collaboration between CStone and Bayer assessing the safety, tolerability, pharmacokinetics, and antitumor activity of the CS1001 plus regorafenib combination in cancer.

    Brand Name : Undisclosed

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    January 24, 2020

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Bayer to showcase new data including research in immuno-oncology at ASCO GI Cancers Symposium 2020

    Details:

    Data to include early analyses of Stivarga® (regorafenib) across HCC, CRC and GI cancers, including Phase 1b data in combination with immuno-oncology therapies.


    Lead Product(s): Regorafenib,Pembrolizumab,Nivolumab

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 21, 2020

    blank

    07

    Bayer AG

    Germany
    arrow
    Antibody Engineering
    Not Confirmed

    Bayer AG

    Germany
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Regorafenib,Pembrolizumab,Nivolumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Bayer to showcase new data including research in immuno-oncology at ASCO GI Cancers Symposium 2020

    Details : Data to include early analyses of Stivarga® (regorafenib) across HCC, CRC and GI cancers, including Phase 1b data in combination with immuno-oncology therapies.

    Brand Name : Undisclosed

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    January 21, 2020

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDF Dossiers

    read-more
    read-more

    01

    NanoAlvand

    Iran
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothNanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

    Contact Supplier Contact Supplier
    Flag Iran
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Iran

    Regorafenib

    Brand Name : Fenosa

    Dosage Form : Film Coated Tablet

    Dosage Strength : 40MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Iran

    NanoAlvand

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Bayer AG

    Germany
    Antibody Engineering
    Not Confirmed
    arrow

    Bayer AG

    Germany
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Germany
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : RX

    Registration Country : USA

    REGORAFENIB

    Brand Name : STIVARGA

    Dosage Form : TABLET;ORAL

    Dosage Strength : 40MG

    Packaging :

    Approval Date : 2012-09-27

    Application Number : 203085

    Regulatory Info : RX

    Registration Country : USA

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Bayer AG

    Germany
    Antibody Engineering
    Not Confirmed
    arrow

    Bayer AG

    Germany
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Germany
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : USA

    REGORAFENIB

    Brand Name : STIVARGA

    Dosage Form : TABLET; ORAL

    Dosage Strength : 40MG

    Packaging :

    Approval Date :

    Application Number : 204369

    Regulatory Info :

    Registration Country : USA

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Bayer AG

    Germany
    Antibody Engineering
    Not Confirmed
    arrow

    Bayer AG

    Germany
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Germany
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Italy

    Regorafenib

    Brand Name : Stivarga

    Dosage Form : Regorafenib 40Mg 84 Combined Oral Use

    Dosage Strength : 84 cpr riv 40 mg vial

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Italy

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Bayer AG

    Germany
    Antibody Engineering
    Not Confirmed
    arrow

    Bayer AG

    Germany
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Germany
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Norway

    Regorafenib

    Brand Name : Stivarga

    Dosage Form : Antic-calc Tablet, Film Coated

    Dosage Strength : 40 mg

    Packaging : Bottle

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Norway

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Bayer AG

    Germany
    Antibody Engineering
    Not Confirmed
    arrow

    Bayer AG

    Germany
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Germany
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Switzerland

    Regorafenib

    Brand Name : Stivarga

    Dosage Form : Filmtable

    Dosage Strength : 40mg

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Bayer AG

    Germany
    Antibody Engineering
    Not Confirmed
    arrow

    Bayer AG

    Germany
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Germany
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Canada

    REGORAFENIB

    Brand Name : STIVARGA

    Dosage Form : TABLET

    Dosage Strength : 40MG

    Packaging : 28

    Approval Date :

    Application Number : 2403390

    Regulatory Info : Prescription

    Registration Country : Canada

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Bayer AG

    Germany
    Antibody Engineering
    Not Confirmed
    arrow

    Bayer AG

    Germany
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Germany
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Originator

    Registration Country : South Africa

    Regorafenib

    Brand Name : Stivarga 40 mg

    Dosage Form : TAB

    Dosage Strength : 40mg

    Packaging : 28X3mg

    Approval Date :

    Application Number :

    Regulatory Info : Originator

    Registration Country : South Africa

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Laboratorio Eczane Pharma

    Argentina
    Antibody Engineering
    Not Confirmed
    arrow

    Laboratorio Eczane Pharma

    Argentina
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Argentina
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Argentina

    Regorafenib

    Brand Name : Rezitix

    Dosage Form : Tablet

    Dosage Strength : 40MG

    Packaging : 28 Tabs

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Argentina

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    ORIFARM GROUP AS

    Denmark
    Antibody Engineering
    Not Confirmed
    arrow

    ORIFARM GROUP AS

    Denmark
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Denmark
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Norway

    Regorafenib

    Brand Name : Stivarga

    Dosage Form : Antic-calc Tablet, Film Coated

    Dosage Strength : 40 mg

    Packaging : Bottle

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Norway

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Listed Dossiers

    read-more
    read-more

    01

    NanoAlvand

    Iran
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothNanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

    Contact Supplier Contact Supplier
    Flag Iran
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Iran

    Regorafenib

    Brand Name : Fenosa

    Dosage Form : Film Coated Tablet

    Dosage Strength : 40MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Iran

    NanoAlvand

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    01

    NanoAlvand

    Iran
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothNanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

    Contact Supplier Contact Supplier
    Flag Iran
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Packaging :

    Regulatory Info :

    Regorafenib

    Dosage : Film Coated Tablet

    Dosage Strength : 40MG

    Brand Name : Fenosa

    Approval Date :

    Application Number :

    Registration Country : Iran

    NanoAlvand

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Laboratorio Eczane Pharma

    Argentina
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Laboratorio Eczane Pharma

    Argentina
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Argentina
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Argentina

    Regorafenib

    Brand Name : Rezitix

    Dosage Form : Tablet

    Dosage Strength : 40MG

    Packaging : 28 Tabs

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Argentina

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Laboratorio Eczane Pharma

    Argentina
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Laboratorio Eczane Pharma

    Argentina
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Argentina
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Packaging : 28 Tabs

    Regulatory Info :

    Regorafenib

    Dosage : Tablet

    Dosage Strength : 40MG

    Brand Name : Rezitix

    Approval Date :

    Application Number :

    Registration Country : Argentina

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Pluviaendo

    Turkey
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Pluviaendo

    Turkey
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Turkey
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Turkey

    Regorafenib

    Brand Name :

    Dosage Form : Tablet

    Dosage Strength : 40MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Turkey

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Pluviaendo

    Turkey
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Pluviaendo

    Turkey
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Turkey
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Packaging :

    Regulatory Info :

    Regorafenib

    Dosage : Tablet

    Dosage Strength : 40MG

    Brand Name :

    Approval Date :

    Application Number :

    Registration Country : Turkey

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Granulation

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Topical

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Finished Drug Prices

    read-more
    read-more

    01

    Brand Name : Stivarga

    Germany
    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Stivarga

    Germany
    arrow
    Antibody Engineering
    Not Confirmed

    Bayer Pharma AG

    Regorafenib

    Dosage Form : Antic-calc Tablet, Film Coated

    Dosage Strength : 40 mg

    Price Per Pack (Euro) : 3,335.17

    Published in :

    Country : Norway

    RX/OTC/DISCN :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Stivarga

    Denmark
    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Stivarga

    Denmark
    arrow
    Antibody Engineering
    Not Confirmed

    Orifarm AS

    Regorafenib

    Dosage Form : Antic-calc Tablet, Film Coated

    Dosage Strength : 40 mg

    Price Per Pack (Euro) : 3,335.17

    Published in :

    Country : Norway

    RX/OTC/DISCN :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Stivarga

    Germany
    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Stivarga

    Germany
    arrow
    Antibody Engineering
    Not Confirmed

    Bayer (Schweiz) AG

    Regorafenib

    Dosage Form : Filmtable

    Dosage Strength : 40mg

    Price Per Pack (Euro) : 2963.85

    Published in :

    Country : Switzerland

    RX/OTC/DISCN : Class A

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Stivarga

    Germany
    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Stivarga

    Germany
    arrow
    Antibody Engineering
    Not Confirmed

    BAYER PHARMA AG

    Regorafenib

    Dosage Form : Regorafenib 40Mg 84 Combined Ora...

    Dosage Strength : 84 cpr riv 40 mg vial

    Price Per Pack (Euro) : 3,276.87

    Published in :

    Country : Italy

    RX/OTC/DISCN : Class A

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search